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RESEARCH ARTICLE
Investigation of procoagulant activity in extracellular vesicles isolated by
differential ultracentrifugation
Thøger Nielsen *a,b, Anne Flou Kristensen *a,b, Shona Pedersen a,b, Gunna Christiansenc
and Søren Risom Kristensen a,b
aDepartment of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark; bDepartment of Clinical Medicine, Aalborg University,
Aalborg, Denmark; cDepartment of Biomedicine, Aarhus University, Aarhus, Denmark
ABSTRACT
Tissue factor (TF) is the main initiator of coagulation and procoagulant phospholipids (PPL) are
key components in promoting coagulation activity in blood. Both TF and PPL may be presented
on the surface of extracellular vesicles (EVs), thus contributing to their procoagulant activity.
These EVs may constitute a substantial part of pathological hypercoagulability that is responsible
for triggering a higher risk of thrombosis in certain patients. The aim of this study was to describe
a model system for the isolation of EVs required for investigating their effect on coagulation.
Differential ultracentrifugation (DUC) with and without a single washing step was used to isolate
and evaluate the procoagulant capacity of EVs from healthy volunteers through analysis of
thrombin generation and PPL activity. Ultracentrifugation at 20,000 × g and 100,000 × g resulted
in pellets containing larger vesicles and smaller vesicles, respectively. Isolation yield of particle
concentration was assessed by nanoparticle tracking analysis. Immunoelectron microscopy and
western blotting revealed vesicles positive for the commonly used EV-marker CD9. Plasma
proteins and lipoproteins were co-isolated with the EVs; however, application of a washing
step clearly diminished the amount of contaminants. The isolated EVs were capable of enhancing
thrombin generation, mainly due to PPL predominantly present in pellets from 20,000 × g
centrifugation, and correlated with the activity measured by a PPL activity assay. Thus, DUC
was proficient for the isolation of EVs with minimal contamination from plasma proteins and
lipoproteins, and the setup can be used to study EV-associated procoagulant activity. This may be
useful in determining the procoagulant activity of EVs in patients at potentially increased risk of
developing thrombosis, e.g. cancer patients.
Abbreviations: TF: Tissue factor; PL: Phospholipids; EVs: Extracellular vesicles; FXa: Activated
coagulation factor X; TGA: Thrombin generation assay; PPL: Procoagulant phospholipids; DUC:
Differential ultracentrifugation; NTA: Nanoparticle tracking analysis; TEM: Transmission electron
microscopy; SPP: Standard pool plasma; CTI: Corn trypsin inhibitor; 20K: 20,000 × g; 100K:
100,000 × g; FVIII: Coagulation factor VIII
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The coagulation processes in haemostasis are mainly
initiated by tissue factor (TF). An important cofactor in
haemostasis, besides calcium, is anionic phospholipids
(PL); this procoagulant factor is necessary for the for-
mation of the important coagulation complexes bind-
ing to this surface. Membrane-associated TF, and
anionic PL, mainly phosphatidylserine, are embedded
in the membrane of extracellular vesicles (EVs) circu-
lating in the blood [1,2]. EVs are commonly divided
into smaller vesicles, mainly exosomes, and larger vesi-
cles, mainly microvesicles, dependent on size,
biogenesis, and phenotypic origin [3,4]. It is probably
mostly microvesicles that carry TF and phosphatidyl-
serine and therefore, they are possibly the most pro-
coagulant of the EVs [5,6]. EVs are elevated in the
blood of patients in a variety of diseases, such as
cancer, and may play a significant role in the develop-
ment of venous thromboembolism [7–9].
Isolating exosomes and microvesicles can be
achieved through various techniques, including size
exclusion chromatography, immunoaffinity precipita-
tion, and ultracentrifugation, however, each technique
has both advantages and limitations [10]. There are
different available methods to study the procoagulant
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activity of EVs. Hisada et al. describes two assays to
measure microvesicle TF-dependent generation of acti-
vated coagulation factor X (FXa) [11]. Another
approach is to evaluate the overall procoagulant effect
of EVs by using a modified version of the thrombin
generation assay (TGA) described by Hemker et al.
[12]. This has been tested in patients with thrombosis
or cancer [13,14]. Marchetti and co-workers [15]
reported evidence of procoagulant phospholipid (PPL)
activity in thrombocythemia patients using a combina-
tion of TGA and a PPL activity assay. However, the
methods available to study the procoagulant effect of
EVs retain certain limitations. Thus, the combination
of assays with increased sensitivity towards TF and
phosphatidylserine and quantitative and phenotypical
analyses of EVs may convey a more accurate profile of
procoagulant EV activity. This may, in a clinical per-
spective, help clarify the role of EVs in coagulation in
identifying certain procoagulant patient groups or indi-
vidual patients at risk of developing venous
thromboembolism.
Therefore, the aim of this study was to compare the
procoagulant effect of EVs of different sizes isolated
from healthy donors using differential ultracentrifuga-
tion (DUC) and to examine whether a post isolation
washing step is imperative for the preparation of an EV
sample devoid of lipoproteins and plasma remnants.
DUC was chosen as it is a commonly used isolation
method for the preparation of EVs. The isolated EVs
were quantitated and validated for specific phenotypi-
cal features using nanoparticle tracking analysis (NTA),
western blot, and transmission electron microscopy
(TEM) with immunogold labelling. The procoagulant
effect of the isolated EVs was investigated by TGA and
a PPL activity assay.
Materials and methods
Sample collection and EV isolation
To examine the procoagulant effect of EVs, blood was
collected from 12 healthy fasting volunteers in the
morning. Six of these 12 donors also delivered samples
to test the effect of contact activation inhibition by
corn trypsin inhibitor (CTI). All volunteers had given
informed consent and the study was conducted in
accordance with the Declaration of Helsinki. Blood
samples were collected from the antecubital vein with
tourniquet and a 21-gauge needle in 6 ml 3.2%
(0.105 M) citrated tubes (BD Vacutainer, BD
Biosciences, San Jose, CA, USA). The blood samples
were left 15 min at room temperature after collection,
before platelet-free plasma was extracted by a double
centrifugation at 2,500 × g for 15 min according to
international recommendations [10,16], leaving 1 cm
plasma both above the buffy coat and the pellet in the
subsequent centrifugation step. Platelet-free-plasma
was obtained within one hour from blood collection.
Standard pooled plasma (SPP) was collected once from
one donor in 6 ml standard citrate tubes and once from
another donor in 4.5 ml specialized corn trypsin inhi-
bitor (CTI) tubes (final concentration of CTI in blood:
50 µg/ml CTI, Haematologic Technologies, Essex
Junction, VT, USA) annotated SPP and SPP+CTI,
respectively. SPP and SPP+CTI were extracted by dou-
ble-centrifugation at 2,500 × g for 15 min similarly to
the procedure described above. Larger EVs were pel-
leted from 1 ml plasma at 20,000 × g (20K) for 30 min
at 4°C. The supernatant was further centrifuged at
100,000 × g (100K) for 60 min at 4°C to pellet smaller
EVs. Pellets resuspended in SPP+CTI were subjected to
a washing step after the initial centrifugation step by
resuspension in 1 ml phosphate-buffered saline (PBS)
and re-centrifugation at the same g-force. For direct
comparison of washed and non-washed pellets on
thrombin generation an additional portion of blood
for SPP was obtained from one of the initial SPP
donors. Followed by the initial preparation of plate-
let-free-plasma, this portion of SPP was eventually
deprived of EVs using a 100,000 × g centrifugation
for 60 min at 4°C. EV isolation was performed in an
Avanti J-30i ultracentrifuge with a JA-30.50 rotor,
k-factor 280 (Beckman Coulter, Brea, CA, USA). All
pellets, washed and unwashed, were finally resus-
pended in either 200 µl SPP or SPP+CTI (i.e. these
suspensions had a 5-fold higher concentration of EVs)
for TGA and PPL activity assay or PBS for NTA, TEM,
western blot, and protein assay. All plasma samples and
EV suspensions were stored at −80°C until analysis.
Nanoparticle tracking analysis
Particle concentration and size determination was mea-
sured using NTA and performed on a LM10-HS sys-
tem (Malvern Instruments Ltd, Malvern, UK) equipped
with a 405 nm laser and a Luca-DL EMCCD camera
(Andor Technology, Belfast, UK). The analysis was
performed to confirm isolation of particles in the EV
size range. Silica Microspheres (0.1 µm, Polysciences,
Hirchberg, Germany) were used as standard to estab-
lish software settings. For analysis, samples were
diluted in PBS to obtain an average of 20–80 particles
per frame and a total of 5 × 30 s videos were captured
for each sample. The specific settings used were camera
level 10, detection threshold 2, and blur 9 × 9 were
employed. The addition of 0.03% Tween 20 (Bio-Rad,
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Copenhagen, Denmark) would prevent EVs in the sus-
pensions from aggregating [17] and this way amend
the outcome of the NTA, therefore, this was also eval-
uated. Data was processed by the Nanosight NTA soft-
ware version 3.0 (Malvern Instruments Ltd, Malvern,
UK) to determine particle concentration and size.
Transmission electron microscopy and immunogold
labelling
TEM was used for the structural characterization of
isolated EVs. TEM was performed according to the pro-
tocol adopted by Vogel et al. [17]. Procedurally, five
microliters of EV suspension was mounted on a carbon
coated, glow discharged 300-mesh nickel grid (SPI
Supplies, Chester, PA, USA) for 30 s, then stained with
1 to 3 drops of 1% (w/v) phosphotungstic acid (Ted
Pella, Caspilor AB, Lindingö, Sweden), pH 7.0, for 15 s
and blotted dry for a few seconds on filter paper. EV
marker CD9 was used for phenotypic characterization of
vesicles. For immunogold labelling, samples were posi-
tioned for 30 s on an identical grid as described above
and washed 3 × 5 min in PBS. Subsequently, the grids
were blocked for 5 min in one drop 0.5% ovalbumin
(Sigma-Aldrich, St. Louis, MO, USA) in PBS. After
blockage, the grids were incubated in one drop of pri-
mary anti-CD9 antibody (clone M-L13, BD Pharmingen,
San Jose, CA, USA) 1:50 in 0.5% ovalbumin in PBS for
30 min at 37°C. After incubation, grids were washed
3 × 5 min in PBS and incubated with secondary goat
anti-mouse antibody conjugated to 10 nm colloidal gold
(British BioCell, Cardiff, UK) 1:25 in 0.5% ovalbumin in
PBS for 30 min at 37°C. Grids were subsequently washed
with 3 drops of PBS for 5 min, before incubation on 3
drops of 1% cold fish gelatin (Sigma-Aldrich, St. Louis,
MO, USA) in PBS for 10 min each. The grids were finally
washed 3 × 5 min in PBS, before negative staining with 1
drop of 1% (w/v) phosphotungstic acid at pH 7.0 and
blotted dry for a few seconds. Images were obtained with
a transmission electron microscope (JEM 1010, JEOL,
Eching, Germany) operated at 60 keV coupled to an
electron-sensitive CCD camera (KeenView, Olympus,
Center Valley, PA, USA). For size determination of
visible EVs, a grid-size replica (2,160 lines/mm) and the
ImageJ 1.50r software (NIH, Bethesda, MD, USA) was
used.
Western blotting
Western blotting was used to validate the isolated EVs
for EV-associated proteins, and was conducted using
the common EV marker CD9 and coagulation protein
TF. Additionally, lipoprotein contamination was
determined by examining apolipoprotein B levels in
the pellets. Pellet-material subjected to SDS-PAGE con-
sisted of a single EV suspension pool (equal volume
from all donors). Proteins were separated in
MiniProtean TGX 4–15% gels (Bio-Rad, Copenhagen,
Denmark) under non-reducing conditions. EV suspen-
sions were loaded in equal amounts, i.e. 10 µl of each
EV suspension pool were diluted 1:1 with Laemmli
sample buffer (Bio-Rad, Copenhagen, Denmark) and
20 µl were loaded into each designated lane in order to
enable relative comparisons between samples on the
same gel in the following analysis of markers. The
proteins were then transferred to Amersham Hybond
0.45 PVDF blotting membranes (GE Healthcare,
Broendby, Denmark) and blocked for 1 h in 5% (w/v)
skim milk in Tris-Glycine buffer. Primary antibodies
were mouse monoclonal anti-human CD9 (clone
M-L13, BD Pharmingen, San Jose, CA, USA), mono-
clonal mouse anti-CD142 (clone HTF-1, BD
Pharmingen, San Jose, CA, USA), or monoclonal
mouse apolipoprotein B (clone F2C9, Thermo
Scientific, Waltham, MA, USA). All primary antibodies
were diluted 1:1000 in 5% (w/v) skim milk in Tris-
Glycine buffer and incubated with the membranes
overnight at 4°C. Secondary labelling was performed
with horseradish peroxidase-conjugated polyclonal
goat anti-mouse antibodies (Dako, Glostrup,
Denmark, 1:30,000 dilution, 2 h at room temperature).
Antibody positive controls were: platelet lysate for
CD9, diluted plasma for apolipoprotein B, and plasma
from LPS-stimulated blood for TF. Samples were devel-
oped with ECL Prime Western Blotting detection
reagent (GE Healthcare, Broendby, Denmark) and
detected on a PXi 4 system (Syngene, Cambridge,
UK) with the GeneSys software 1.5.4.0 (Syngene,
Cambridge, UK). Band intensity was determined with
the ImageJ 1.50r software (NIH, Bethesda, MD, USA)
to compute relative differences in marker expression
between the different pellet pools.
Protein and factor VIIIa quantitation
In order to determine the extent of co-isolation of
larger coagulation factors, the activity of coagulation
factor VIII (FVIII) in the EV suspensions dissolved in
PBS was determined by performing a modified acti-
vated partial thromboplastin time test (HemosIL and
SynthASil, Instrumentation Laboratory, München,
Germany), using FVIII-deficient plasma and optimized
for low concentrations of FVIII, on an ACL TOP 500
CTS system (Instrumentation Laboratory, München,
Germany). Total protein content of the pellet suspen-
sions was analysed with the Pierce BCA Protein Assay
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Kit (Thermo Scientific, Waltham, MA, USA) on a
Fluostar Optima (BMG Labtech, Ortenberg,
Germany) at wavelength 562 nm. Measurement of
haemoglobin, leucocytes, and platelets were performed
on a Sysmex XN-9000 Automated Hematology System
(Sysmex Corporation, Kobe, Japan).
Thrombin generation assay
The thrombin generation in SPP (n = 12) or SPP+CTI
(n = 6) spiked with EVs was measured using the
calibrated automated thrombogram as described by
Hemker et al. [12] by mixing 80 µl of each sample
with 20 µl trigger reagent and 20 µl buffer containing
a fluorogenic substrate and CaCl2 (FluCa kit,
Thrombinoscope BV, Maastricht, The Netherlands).
Thrombin generation was triggered with one of three
different reagents, i.e. MP (4 µM PL), PRP (1 pM TF),
and PPPlow (1 pM TF and 4 µM PL, Thrombinoscope
BV, Maastricht, The Netherlands), or without addition
of supplementary PL or TF (no trigger reagent). Each
sample was calibrated against calibrator containing a
fixed amount of thrombin-α2-macroglobulin complex
(Thrombin Calibrator, Thrombinoscope BV,
Maastricht, The Netherlands) diluted in the same sam-
ple. To determine the TF-associated thrombin genera-
tion when using no trigger, thrombin generation was
assessed in SPP spiked with the isolated EVs in the
presence and absence of anti-CD142 (clone HTF-1).
Additionally, thrombin generation in washed com-
pared to unwashed pellets was determined using no
trigger and the three different reagents in three of the
donors. The reaction was monitored on a fully auto-
mated and computer-controlled Fluoroscan Ascent
(Thermo Scientific, Waltham, MA, USA) with a 390/
460 filter set using the Thrombinoscope software 5.0
(Thrombinoscope BV, Maastricht, The Netherlands).
Procoagulant phospholipid activity assay
PPL activity in SPP spiked with the unwashed EVs was
analysed with the FXa-based clotting STA-Procoag PPL
kit (Stago, Asnières, France). The test measures a clot-
ting time solely dependent on PPL in the sample, i.e.
the more PPL activity the shorter clotting time. EV
suspension, 25 µl, diluted 1:1 in Owren-Koller buffer
(Stago, Asnières, France) were mixed with 25 µl PL-free
plasma and triggered with 100 µl 0.001 IU FXa and
0.025 M CaCl2. The clotting time was measured on an
automated STA-Compact (Stago, Asnieres, France) in
agreement with the manufacturer’s protocol.
Statistical analysis
Data are expressed as mean ± standard deviation.
Parametric (Student’s t-test) or nonparametric
(Mann-Whitney U test) was used to compare differ-
ences in particle size, particle quantity, and coagulation
activity of the different pellet types, including washed/
unwashed and ±CTI. Paired samples t-test was used to
detect differences between paired groups, e.g. compar-
ison of washed and unwashed pellets and effect of
washing. Pearson correlation coefficient was used to
identify associations between coagulation assays and
NTA measurements. All statistical analyses were per-
formed using IMB SPSS Statistics 23 (SPSS, Chicago,
IL, USA) and Graph Pad Prism 6 (GraphPad Software,
La Jolla, CA, USA).
Results
Donor characteristics
The donors were all healthy with a mean age of
35 years (range 23–63) and comprised 6 males and 6
females. None of the donors were on pain medication
prior to sample collection. One female used progesto-
gen-only pills. All donors had a complete haematology
investigation, including erythrocytes, haemoglobin,
leucocytes, and platelets. All values were within normal
reference ranges.
EV isolation
When compared to the original plasma particle con-
centration, the amount of particles isolated in the
unwashed pellets was approximately 5–8% and for the
washed pellets less than 1% (Table 1). On average,
there were significantly more particles in the 100K
pellets compared to the 20K pellets in unwashed pellets
(42%, P < 0.05, Figure 1(a)) and the mean size was
13 nm smaller (11%, P < 0.05, Figure 1(b)).
Introduction of a single washing step, resulted in
reduced particle concentrations in the pellets to almost
5% of the equivalent unwashed pellet (P < 0.01). While
comparing the individual donors, the mean particle
size in the 20K pellets was 32 nm larger (P < 0.01)
than their subsequent 100K pellets in washed pellets.
Furthermore, the washed 20K pellets were generally
larger than their corresponding unwashed 20K pellets
(31%, P < 0.05, Table 1). A substantial overlap in
distribution of particle size was observed between pel-
lets, although the 20K pellets contained approximately
50% more particles larger than 200 nm independent of
whether washing was applied or not. Moreover, it was
clear that washing increased the fractions of particles
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above 100 nm in size, especially in the 20K pellets
(Figure 1(c)). The addition of 0.03% Tween 20 to
eliminate eventual aggregation of the isolated EV pel-
lets, resulted in similar NTA measurements compared
to no detergent (data not shown). The particles were
analysed by electron microscopy to confirm the pre-
sence of EVs and to detect possible EV subpopulations.
TEM revealed structures that resembled EVs of various
sizes (Figure 2(a,b)). Immunogold labelling identified
several EVs of different sizes that were positive for CD9
in both washed and unwashed pellets. For the washed
100K pellets, the relative intensity extrapolated from
the western blotting band revealed a reduction of
almost 50% in CD9 expression, whereas the CD9
expression in the 20K pellets remained unchanged
(Figure 2(f)). Additionally, for the unwashed samples,
a faint TF (CD142, clone HTF-1) band was detected in
both 20K and 100K pellets (3-fold higher in the 20K
pellets), however, washing resulted in the loss of the TF
bands.
The images from TEM revealed that a substantial
amount of small particles (<50 nm) are co-isolated in
the unwashed pellets, but this co-isolation was consider-
ably reduced when pellets were washed (Figure 2(a-c)).
In some cases, predominantly in unwashed pellets, it
appeared that these smaller particle-shaped structures
adhered to or resided in proximity to larger particles
(Figure 2(e)). Apolipoproteins-B100 and -B48 were pre-
sent in unwashed pellets with approximately 90% of the
apolipoproteins being present in the 20K pellet pool and
10% in the 100K pellet pool (Figure 2(f)). After washing,
apolipoprotein B bands were not present in either pellet
type. The protein content of the pellets pools was quan-
titated to determine the extent of co-isolated plasma
proteins (potentially including coagulation factors).
After introduction of a single washing step, the protein
content in 20K pellets was reduced from
2158.1 ± 68.3 µg/ml to 50.1 ± 0.7 µg/ml and the 100K
pellets from 1276.9 ± 36.9 µg/ml to 146.9 ± 2.3 µg/ml,
i.e. a reduction in protein content of 88–98% in the two
pellet types. Moreover, FVIII measurement did not
reveal any activity in either pellet type.
EVs effect on coagulation
To demonstrate the potential role of EVs in coagulation,
the isolated EVs resuspended in SPP were measured
using TGA without or in the presence of three different
trigger reagents (Figure 3). EVs “spiked” into SPP and
analysed without trigger reagent resulted in thrombo-
grams depicting an overall increase in thrombin genera-
tion compared to non-spiked SPP, especially for the 20K
pellets but with a considerable inter-individual variation
Table 1. The main findings from NTA.
Original plasma 20K pellets P-value 100K pellets P-value
Unwashed pellets (n = 12)
Particle concentration (part./ml) 1,66E+12 ± 1,28E+12 9,23E+10 ± 4,37E+10 <0.01 1,31E+11 ± 8,85E+10 <0.01
Mean particle size (nm) 85 ± 13 119 ± 14 <0.001 106 ± 11 <0.001
Washed pellets (n = 6)
Particle concentration (part./ml) 1,45E+12 ± 9,34E+11 5,73E+09 ± 1,24E+09 <0.05 8,31E+09 ± 2,97E+09 <0.05
Mean particle size (nm) 82 ± 6 158 ± 11 <0.0001 126 ± 12 <0.001
Significantly less particles were present in the pellets compared to the original donor plasma, but these had a larger mean particle size. A series of 5 × 30 s
videos were taken for each sample. P values are representing the findings from the pellets compared against the original donor plasma. The videos were
captured at camera level 10 and the particles tracked at detection threshold 2 with 9 × 9 blur.
Figure 1. NTA performed on pellets. (A) Concentration of particles and (B) size determination of particles in each pellet group.
*P < 0.05. **P < 0.01. ***P < 0.001. (C) Size distribution of the different pellets divided into three fractions, i.e. <100 nm,
100–200 nm, and >200 nm. EV suspensions were diluted to obtain a particle count per frame within the recommended limits.
Capture duration was 5 × 30 s at camera level 10 and the videos were analysed at detection threshold 2 with 9 × 9 blur.
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(Figure 3). Using theMP reagent, containing only PL, this
variation diminished. Inhibition of TF activity with anti-
CD142 (clone HTF-1) resulted in little or no changes to
the thrombin generation profile, thus indicating that TF
is not the determining factor when using no trigger
reagents (Supplementary Figure 1). When the pellets
were resuspended in SPP+CTI, little or no thrombin
was generated when using no trigger or the MP reagent.
When thrombin generation was triggered with the PRP
reagent (TF but no PL), both 20K and 100K pellets
demonstrated an increased thrombin generation in SPP
and SPP+CTI, with the 20K pellet exhibiting the most
profound thrombin generation effect. When the PPPlow-
reagent was used to trigger coagulation, the overall
thrombin generation was higher with the 100K pellets
compared to the 20K pellets (Figure 3(g)). This observa-
tion was consistent for EVs from all healthy volunteers,
however, this was not apparent when SPP+CTI were used
(Figure 3 (h).
In order to directly compare the effect of a washing
step on coagulation, thrombin generation was per-
formed on samples treated with or without washing.
The ratio between the various measures of thrombin
generation on washed and unwashed pellets are shown
in (Table 2). In general, the calculated ratios were close
to 1.0 (i.e. no effect of washing), although, there was a
tendency of a minor decrease in thrombin generation
from the washed pellets. This effect, however, was not
Figure 2. TEM and western blotting was applied to verify the presence of EV subpopulations in both washed and unwashed pellets.
TEM showing EV-characteristics, i.e. shape and size in (A) unwashed and (B) washed pellets. Immunogold labelling with anti-CD9
(clone M-L13) bound to EVs in unwashed (C) and washed (D) pellets confirming presence of CD9-positive subpopulations. (E) Small
(<50 nm) vesicular structures adhering to or residing in proximity to larger vesicles. (F) Western blot with anti-CD9, anti-CD142
(clone HTF-1), and anti-apolipoprotein B (clone F2C9) on a pellet pool for each pellet type showing the presence of EV marker CD9
and the removal of apolipoprotein B after washing in PBS.
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significant and inconsistent between the different
donors.
PPL in the pellets shortened the PPL clotting time
with the most pronounced effect among 20K pellets
(Figure 4(a)). The 20K pellets reduced the clotting time
by almost 44% (P < 0.001), whereas the 100K pellets
only resulted in an 18% reduction (P < 0.01) on aver-
age. The PPL activity correlated strongly with throm-
bin generation measured with PRP-reagent (containing
only TF); Figure 4 (b) depicts the correlation between
peak of thrombin generation and PPL clotting time.
This correlation disappeared when PPL clotting time
Figure 3. Thrombograms (mean ± SEM) depicting the effect on thrombin generation of EV-containing pellets “spiked” into SPP with
(n = 6) or without (n = 12) collected with CTI. PBS was added to the standard pool plasma that was not spiked with EVs (control).
Thrombograms were generated with different trigger either MP, PRP, or PPPlow reagent or without addition of trigger reagents
(depicted vertically). The effect of EVs on thrombin generation seems to mainly be driven by PPL. The use of CTI is depicted in the
horizontally.
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was correlated to thrombin generation measured with
PPPlow-reagent (containing both TF and PL). There
appears to be a correlation between the mean particle
size and PPL activity in the 20K pellets, where a larger
mean particle size is equivalent to a shorter PPL clot-
ting time, i.e. increased PPL activity (Figure 4 (c),
although not significant (P = 0.092). This trend was
only present when the pellets were washed. The main
findings in TGA and PPL activity assay are summar-
ized in (Table 3).
Examining the activity in the supernatants after centri-
fugation and removal of first 20K and subsequently 100K
supernatants showed a markedly reduced thrombin gen-
eration compared to the original plasma (Figure 5(a)), and
this observation was consistent and independent of trigger
reagent used. PPL activity decreased in a similar way, i.e.
Table 2. The effect of a single washing step on thrombin generation using no trigger reagent, MP, PRP, or
PPPlow.
ETP (nM*min) Peak thrombin (nM) Lag time (min) Time-to-peak (min)
No reagent
20K pellets 1.08 ± 0.07 0.83 ± 0.17 1.14 ± 0.10 1.14 ± 0.10
100K pellets 0.88 ± 0.14 0.71 ± 0.36 1.25 ± 0.22 1.24 ± 0.26
MP reagent
20K pellets 1.03 ± 0.07 0.97 ± 0.07 1.05 ± 0.12 1.05 ± 0.10
100K pellets 0.95 ± 0.11 1.00 ± 0.20 1.17 ± 0.12 1.13 ± 0.12
PRP reagent
20K pellets 1.21 ± 0.17 1.00 ± 0.21 1.03 ± 0.04 1.06 ± 0.06
100K pellets 1.18 ± 0.07 0.71 ± 0.12 1.08 ± 0.10 1.20 ± 0.15
PPPlow reagent
20K pellets 1.14 ± 0.31 1.06 ± 0.27 1.06 ± 0.02* 1.02 ± 0.04
100K pellets 1.21 ± 0.14 1.23 ± 0.23 0.97 ± 0.07 0.97 ± 0.05
Parameters ETP, peak thrombin, lag time, and time-to-peak are presented as a mean ± SD of a ratio (washed/unwashed) calculated
for both 20K and 100K pellets from each donor. No significant differences are observed between the procoagulant effect of washed
and unwashed pellets, except for lag time in 20K pellets when using PPPlow reagent with a slight increase in washed pellets.
*P < 0.05.
Figure 4. EV-associated PPL activity measured by PPL activity assay. (A) EVs reduce the PPL clotting time of SPP, mainly those in 20K
pellets, thus increasing the PPL activity. The blue and dotted lines represents the reference PPL clotting time (mean ± SD, n = 12) of
SPP without addition of EVs. (B) The 20K pellets showed tendency towards larger particles correlating with increased PPL activity,
although this was not significant. (C) A significant correlation between PPL clotting time and thrombin generation using PRP
reagent (containing no PL) was observed, but this disappeared when using PPPlow reagent (containing PL). *P < 0.001.
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increased PPL clotting times, in both the 20K and 100K
supernatants (Figure 5 (b)).
Discussion
The aim of this study was to establish a method to isolate
plasma EVs for the determination of procoagulant activ-
ity and to examine whether a single washing step is
essential for the removal of lipoproteins and plasma rem-
nants for clinical studies. Using DUC, we isolated EVs of
various sizes and demonstrated that whilst a single
washing step was beneficial for the removal of excess
proteins and lipids, there is a concurrent loss of some
EVs and a minimal effect on coagulation activity. The
TGA and PPL activity assay results of the 5-fold up-
concentrated EVs, clearly indicating that the procoagu-
lant effect is mostly driven by PPL activity from the larger
EVs. Thus, this is a model system to investigate procoa-
gulant EVs potentially present in patients at increased
risk of thrombosis.
EVs are involved in coagulation processes, and it has
been suggested that theymay have a thrombogenic effect in




SPP +20K +100K SPP +20K +100K
No reagent
ETP (nM*min) 570 ± 218 1021 ± 477 884 ± 399
Peak thrombin (nM) 17 ± 1 81 ± 39 46 ± 22
Lag time (min) 28.9 ± 3.4 19.4 ± 4.2 24.5 ± 7.7
Time-to-peak (min) 41.0 ± 3.6 28.7 ± 5.4 35.8 ± 9.3
Velocity index (nM/min) 0.8 ± 0.7 2.2 ± 1.0 4.3 ± 3.0
MP reagent
ETP (nM*min) 888 ± 15 1184 ± 264 1192 ± 241
Peak thrombin (nM) 81 ± 1 105 ± 27 118 ± 43
Lag time (min) 16.3 ± 0.2 18.5 ± 3.6 17.2 ± 2.8
Time-to-peak (min) 23.0 ± 0.2 25.4 ± 4.1 23.5 ± 3.4
Velocity index (nM/min) 12.2 ± 0.1 14.1 ± 7.6 20.7 ± 13.2
PRP reagent
ETP (nM*min) 543 ± 34 1292 ± 209 1071 ± 263 794 ± 283 1426 ± 186 1055 ± 355
Peak thrombin (nM) 18 ± 3 88 ± 29 48 ± 18 25 ± 2 57 ± 13 35 ± 8
Lag time (min) 8.2 ± 0.1 7.3 ± 0.8 8.3 ± 0.8 5.5 ± 0.2 5.8 ± 0.5 6.3 ± 0.2
Time-to-peak (min) 22.3 ± 0.9 17.5 ± 1.9 20.5 ± 1.6 18.8 ± 1.5 19.4 ± 2.0 20.0 ± 1.0
Velocity index (nM/min) 1.3 ± 0.3 9.1 ± 4.3 4.1 ± 1.9 1.8 ± 0.0 4.4 ± 1.4 2.6 ± 0.6
PPPlow reagent
ETP (nM*min) 1219 ± 76 1415 ± 202 1969 ± 289 1009 ± 317 864 ± 239 857 ± 111
Peak thrombin (nM) 120 ± 7 141 ± 36 251 ± 59 90 ± 33 70 ± 26 69 ± 11
Lag time (min) 4.2 ± 0.1 4.5 ± 0.4 4.2 ± 0.5 4.9 ± 0.6 4.7 ± 0.5 4.7 ± 0.7
Time-to-peak (min) 10.3 ± 0.2 10.7 ± 1.3 7.9 ± 1.2 11.1 ± 1.2 12.1 ± 1.4 11.5 ± 1.7
Velocity index (nM/min) 19.7 ± 0.8 27.0 ± 11.6 76.8 ± 40.2 15.2 ± 6.8 10.2 ± 5.8 11.0 ± 3.5
PPL activity assay
PPL clotting time (sec) 70.9 ± 0.8 39.9 ± 7.5 58.0 ± 10.7 68.1 ± 0.4 45.3 ± 11.1 65.7 ± 2.7
Parameters ETP, peak thrombin, lag time, time-to-peak, and velocity index are listed as mean ± SD. Data from TGA with no trigger reagent or using the MP
reagent are not available due to very little to no thrombin generated.
Figure 5. Loss of procoagulant activity from plasma from healthy donors after DUC and EV removal. (A) Thrombin generation (using
PRP reagent) decreased in the donor plasma as result of EV-removal during DUC. Dotted lines represent mean ± SEM. (B) PPL
activity in the donor plasma was reduced significantly after DUC and EV-removal. *P < 0.05; **P < 0.01; ***P < 0.001.
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various diseases. Several methods have been used for EV
isolation, but each method has its advantages and disad-
vantages. We have tested DUC, the most commonly used
isolation technique [18], as it is a simple approach andhas a
rather high throughput. Furthermore, it has the advantage
that EVs are concentrated in a pellet suitable for undiluted
resuspension in SPP for further coagulation analysis. A
disadvantage of DUC is that non-EV components with
similar dimensions and densities are also isolated with the
EVs and this technique often results in co-isolation of
plasma proteins [19]. Nevertheless, DUC appears to be a
well-suited isolation method for the investigation of the
procoagulant activity of EVs. Ideally, we expect to have
microvesicles in the 20Kpellets and smaller vesicles,mainly
exosomes, in the 100K pellets. However, our results show
that both pellet types contained particles of various sizes;
yet with almost 50% more vesicles >200 nm in the 20K
pellets compared to the 100K pellets (Figure 1 (c)). DUC
has a limited capability to separate EVs by size [20] explain-
ing the size-overlap we observed between 20K and 100K
pellets in unwashed pellets. Washing of pellets in PBS after
the isolation procedure resulted in an overall increase in
mean particle size, a better size-separation between pellet
types, and an overall decrease in particle concentration for
both 20K and 100Kpellets. This, however, results in the loss
of some CD9+ EVs in the 100K pellets. In addition, we
discern that washing of the pellets resulted in an increase in
particles >100 nm and a reduction in the particles <100 nm
in both 20K pellets and 100K pellets. Since the concentra-
tion of the smaller particles was significantly reduced, the
increase in mean particle size could probably be partly
attributed to the removal of lipoproteins, but possibly also
aggregates of proteins or other plasma material (Figure 1
(c)), as it is well known that lipoproteins interfere with the
particle quantitation byNTA [10,21]. This observation was
in accordance with the reduced protein content shown by
protein quantitation, and also the western blot findings,
where we confirmed that the presence of apolipoprotein B,
a marker for both lipoprotein fractions LDL, IDL, VLDL,
and chylomicrons, disappeared upon washing. Through
TEM we observed that small particles (Figure 2 (e)) were
found in close proximity to larger vesicle-like structures,
mainly in the unwashed pellets, and the size of these was
accordant with that of lipoproteins. Ultracentrifugation has
been reported to instigate aggregation of platelet vesicles
[22], but thismay also be the case for lipoproteins andother
vesicle-like structures. Addition of low concentrations of
Tween 20 in the EV suspensionhas previously beenutilized
to prevent EV aggregation [17]. Nevertheless, we found
that addition of Tween 20 to the samples did not change
particle size and concentration measured by NTA. The
introduction of a washing step seemed advantageous
because the protein content was reduced by more than
88%, which likely eliminates the risk of coagulation factors
(not associated to vesicles) in plasma contaminating the
pellets. FVIII, a relatively high molecular weight protein,
displayed no activity in our pellet material indicating that
the thrombin generation was not influenced by this coagu-
lation protein and probably other coagulation factors.
Western blotting and electron microscopy evidently
showed that CD9+ EVs were present in the pellets, but
also that the CD9 expression in the 100K pellets was
reduced after washing. Additionally, theminute TF expres-
sion found in unwashed pellets was not detectable after
washing, indicating a possible loss of some procoagulant
TF+ EVs. Nevertheless, no significant loss of functionality
in regard to coagulation was observed when the effect of
washingwas testedwith TGA (Table 2). Therefore, it seems
beneficial to include a washing process in the EV isolation
step to diminish plasma contaminants. The washing pro-
cedure adopted to isolate EVs in the present study is similar
to recent research regarding EV-isolation through ultra-
centrifugation [20,23,24]. Although we observed a moder-
ate overlap in EV size distribution in between the two pellet
types, we find DUC suitable to isolate EVs of various sizes
for further analysis of procoagulant activity. Others recom-
mend using DUC combined with a density gradient
[25,26], which may improve the size-separation of EVs,
i.e. microvesicles vs. exosomes, and consequently be a
beneficial addition to the isolation step. However, this
was not done in the present study because we anticipate
that the different types of gradientmedium could influence
the procoagulant capacity EVs and the subsequent coagu-
lation analysis.
The procoagulant activity of the EVs, i.e. the pellets,
was examined with TGA using various trigger reagents
in the presence and/or absence of TF and PL. TF
primarily promotes a faster initiation of thrombin
generation i.e. shorter lag time, whereas PPL primarily
have an effect on the amount of thrombin generated
(peak and ETP) [27]. Using no trigger reagent, where
only isolated EVs and the coagulation factors in SPP
can trigger coagulation, a small but variable amount of
thrombin was generated (Figure 3 (a)). If only PL was
added, i.e. MP reagent, the thrombin generated were
almost the same in original SPP and SPP spiked with
EVs indicating that the differences in (Figure 3 (a))
are mainly driven by PPL on the isolated EVs.
Inhibition with anti-CD142 did not reduce thrombin
generation, thus suggesting that this reaction is mainly
initiated by contact activation and, furthermore, that
healthy donors do not contain any or very little TF+
EVs. Supporting this observation, no thrombin gen-
eration was seen when SPP+CTI was used (Figure 3
(d)), as documented by Boknäs and colleagues [27].
When TF was used as trigger, i.e. PRP reagent, a
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significant difference was observed between pure SPP
and SPP spiked with EVs (Figure 3 (e)). This differ-
ence disappeared for SPP containing 20K pellets when
PL also was added via the trigger reagent, i.e. PPPlow
reagent (Figure 3 (g)), i.e. in accordance with the
presence of PPL in the pellets. However, with both
TF and PL present in the trigger reagent, SPP contain-
ing 100K pellets actually had a higher thrombin gen-
eration than pure SPP and SPP containing 20K pellets.
This was unexpected but most of the donors showed
this difference, although the differences between 20K
and 100K pellets differed substantially. Since this effect
was only apparent when TF as well as PL were added,
it indicates that the 100K pellet may contain some
other factors that increase the coagulation activity.
Measuring PPL with the PPL activity assay demon-
strated that 20K pellets had a higher PPL content than
the 100K pellets. This is in agreement with the corre-
lation between the TGA findings using PRP-reagent
and PPL activity assay (Figure 4 (c)), however, when
PL is supplied by the reagent (PPPlow-reagent) the
correlation between thrombin generation and PPL
activity disappears. Furthermore, we observed a ten-
dency towards a higher PPL activity in the larger
particles (Figure 4 (b)). The removal of 20K pellets
and 100K pellets revealed a reduced activity of PPL in
the subsequent supernatants (Figure 5), similar to
findings by Marchetti et al. [15]. Our findings indi-
cated that EVs from healthy persons carry no or a very
low amounts of TF, but contain some PPL which is
also in agreement with the findings of others [28,29].
Unfortunately, in the present study SPP and SPP
+CTI were drawn from two different donors, and
therefore a comparison of procoagulant activity of
EVs between the two SPP types should be evaluated
with caution. While CTI inhibit contact activation it
may also have an impact on other coagulation factors
[30]. Consequently, it may not be optimal to use
plasma with CTI added, and as an alternative, the
activity of TF can be demonstrated by the addition of
anti-CD142 antibodies. It may be advantageous to
use SPP deprived of EVs, e.g. by ultracentrifugation,
which also was used in the experiment examining the
effect of the washing step on thrombin generation
(Table 2), thus increasing the assay sensitivity.
Nevertheless, in the present study a procoagulant
effect of EVs from different donors was demonstrated
when spiked into SPP not deprived of EVs and was
not much different when ultracentrifuged SPP was
used. In this study, we have used non-pathological
samples having a low TF-activity [28,29]. However, to
determine whether the method described in the pre-
sent study can be used to identify patients at
increased risk of thrombosis warrants further
investigation.
In summary, we have successfully isolated EVs of
different sizes from plasma by DUC and confirm the
presence of an EV population positive for the com-
monly used EV marker CD9. The inclusion of a wash-
ing step after the isolation of EVs appears to be
beneficial for application in EV characterization analy-
sis and coagulation analysis. A combination of TGA,
using different reagents, and a PPL activity assay has
the potential to demonstrate the presence (or not) of
TF and PPL in the EV suspensions which is useful for
the characterization of pathological samples, e.g. from
cancer patients.
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